Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver. This can lead to cirrhosis as scar tissue replaces healthy liver tissue and liver function becomes increasingly impaired.
We are conducting a new research study for individuals with primary biliary cholangitis. The purpose of this research study is to evaluate the effectiveness and safety of a new investigational oral drug, EDP-305.
To qualify volunteers must be:
- Between 18 and 75 years of age
- Diagnosed with primary biliary cholangitis
Taking a stable dose of Ursodeoxycholic Acid (Ursodiol, Actigall, URSO 250, or URSO Forte) for at least 6 months or are not able to take URSO
There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study related drug and medical exams at no cost, as well as reimbursement for expenses incurred because of participation. No health insurance is required to participate.
For more information call:
Or sign up and our office will call you!